Obermatt
See Similar Stocks →

Uniqure

NSQ:QURE · NL0010696654
BiotechnologySmall

360

20
Profit price48
Owner Earnings Yield1
Dividend Yield1
Price/Sales12
Price/Book95
Return on Capital62
Cash Return on Capital15
Return on Equity1
Profit margins26
Accruals13
Owner Earnings Margin10
Sales growth80
Profit growth22
Reinvestment86
Price momentum73
Debt load24
Refinancing31
Debt Payback1
Liquidity54
Analyst ratings28
Opinion Changes50
Price Target Upside32
Market mood17
Value Creation7/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Uniqure clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryNetherlands
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Employees286
Websiteuniqure.com
ISINNL0010696654
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
HematologyNeurologyCentral Nervous SystemGenetic DisorderGeneticsBiotechnologyHealth CareMedical

Description

uniQure N.V., a company in the field of gene therapy, seeks to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. The company is advancing a focused pipeline of innovative gene…

Analysis

Weak and unloved

uniQure N.V. scores below average on quality and is priced accordingly, a low-conviction position in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 7/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
53
2026

All-time high

53

Jun 2026

All-time low

6

Mar 2026

Average rank

30

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
12
—
—
—
Price/Earnings
55
—
—
—
Price/Book
95
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
59
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Uniqure with its peers
Oxford Biomedica
LSE:OXB
40
CountryUK
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
OKYO Pharma
NAQ:OKYO
40
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Tiziana Life Sciences
NAQ:TLSA
67
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
AC Immune
NMQ:ACIU
68
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
ProQR Therapeutics
NAQ:PRQR
19
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
ABIVAX
PAR:ABVX
26
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →